gs1-144
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 2, 2022 (NCT06726850)
Timeline
Indications
Mechanism of action
- Neurokinin 2 receptorANTAGONIST
TACR2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06983925 | Phase 1 | Apr 30, 2025 | GeneScience Pharmaceuticals Co., Ltd. |
| NCT06385158 | Phase 1 | Apr 30, 2024 | GeneScience Pharmaceuticals Co., Ltd. |
| NCT06204250 | Phase 1 | Feb 27, 2024 | GeneScience Pharmaceuticals Co., Ltd., Syneos Health |
| NCT06726850 | Phase 2 | Sep 2, 2022 | GeneScience Pharmaceuticals Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GeneScience Pharmaceuticals Co., Ltd. | For profit | 4 | 4 | 2 | 2022 |
| Syneos Health | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1